Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026
Incyte will present more than 30 abstracts across its hematology portfolio at the ASH 2026 Annual Meeting, December 12-15 in New Orleans. Highlights include oral presentations of first-line myelofibrosis data for INCA033989, its first-in-class mutant calreticulin-targeted antibody, plus updated second-line MF and essential thrombocythemia results, and long-term Phase 1/2 data for latarcibart (VGA039) in von Willebrand disease. An investor and analyst event will be held Saturday, December 12, 2026, 7:30-9:00 p.m.
Key figures
- Abstract count
- more than 30
- Investor event date
- December 12, 2026, 7:30-9:00 p.m. CT
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.